GLP-1 therapies helped drive a 79% year-over-year increase in strategic pharmaceutical M&A deal value through mid-November 2025, as drugmakers ramped up efforts to meet surging demand and expand their metabolic portfolios.
According to Bain & Co.’s Global M&A Report 2026, the spike in activity reflects a shift in strategy: Acquirers are no longer focused solely on individual products, but are instead building full-platform control. That includes securing proprietary delivery technologies, expanding manufacturing capacity and investing in next-generation mechanisms.
This evolution is also reshaping the structure of deals. Bain said transactions are becoming larger and more technically complex, with several including manufacturing tie-ups aimed at alleviating production bottlenecks. At the same time, companies are broadening their pipelines through investments in oral formulations and dual- and triple-agonist therapies.
Beyond infrastructure and R&D, the report points to a growing focus on commercial strategy. As GLP-1s move further into chronic disease management and consumer wellness, Bain said the greatest value will accrue to companies that can integrate innovation, scale supply and connect directly with patients.
GLP-1 makers now account for a significant share of pharma deal value, and Bain expects they will continue to lead sector activity into 2026.
The post GLP-1 momentum drives 79% pharma M&A surge appeared first on Becker's Hospital Review | Healthcare News & Analysis.
Source: Read Original Article
